E-DRUG: EU Paediatric Regulation hardly benefits children
---------------------------------------------------------
Prescrire's response to the EU Commission’s consultation on the first 5 years of application of the Paediatric Regulation.
Dear E-druggers,
Prescrire responded to the consultation on the lessons learnt from the first 5 years of the EU Paediatric Regulation by detailing one example in France that illustrates particularly well some of the most lamentable aspects of the application of this regulation: Cozaar° oral suspension, the paediatric form of the antihypertensive drug losartan.
Cozaar° oral suspension also highlights the failure of the Paediatric Regulation to stimulate the development of the medicines most useful for children.
See Prescrire's response at:
http://english.prescrire.org/en/81/168/48308/0/NewsDetails.aspx
[Fix URL in browser if broken - moderator]
Christophe Kopp
Editor with Prescrire
Website: english.prescrire.org